Analyze Anticoagulants Market with DelveInsight
Anticoagulants are drugs that are given to prevent blood from clotting or prevent existing clots from getting larger. They can keep harmful clots from forming in heart, veins or arteries. Clots can block blood flow and cause a heart attack or stroke. Until recently, the only available oral anticoagulants were the vitamin K antagonists, such as warfarin which is an Injectable solution. In the past few years, however, the landscape has changed with the introduction of new oral anticoagulants that specifically target either factor Xa or thrombin. Rivaroxaban, dabigatran and apixaban, the oral factor Xa inhibitors, are active compounds with an oral bioavailability of more than 50%. The new oral anticoagulants have several advantages over warfarin, including pharmacology, laboratory monitoring, class effects and differentiating effects.
Most drugs are recommended for Deep Vein thromboembolism (DVT) and pulmonary embolisms (PE) while the least being heparin-induced thrombocytopenia, thrombocytopenia, Peripheral vascular occlusion, Non-Q wave myocardial infarction, and disseminated intravascular coagulation. Currently there are 10 drugs and 9 drugs which are used for PE and DVT respectively.
DelveInsight- Anti-coagulant Report, “Anticoagulants-Competitive Landscape, Market & Pipeline Analysis, Forecasted Market Size 2015-2018”.
This DelveInsight report provides a thorough overview of these new oral anticoagulants, their approved indications, drug profiles, pharmacokinetic parameters and market growth, historical sales and forecasted sales of each molecule till 2018. The Report also provides the pipeline information and their drug profiles giving therapeutic analysis by route, mechanism of action and molecule type. The Report has also highlighted the two prevalent indications, Venous Thromboembolism and Atrial Fibrillation, its epidemiology segmented by geography and their current and future market. The Report has also given analysis on the basis of SWOT analysis.
For more information on this report and Sample Pages, mail us at firstname.lastname@example.org